Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
PMID: 33975397
2021
Journal of Korean medical science
Introduction: The SARS-CoV-2 B.1.351 variant in South Africa has eight mutations involving the S protein (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and A701V).
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
Introduction: 11 Virtually all variants of concern contain mutations in the SARS-CoV-2 Spike protein, such as variant B.1.351 (Spike mutations K417N, E484K, N501Y, D614G, and A701V) and variants B.1.427/B.1.429 (Spike mutations S13I, W152C, L452R, and D614G), and many of these reside on the receptor-binding domain (RBD), a region located between residues 350-550 of Spike and directly binding to the human ACE2.
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Introduction: The D253G mutation is located in the amino-terminal supersite that serves as a binding site for neutralizing antibodies, while A701V is located adjacent to the furin processing site.
Introduction: The B.1.526 variant spike proteins contain the D614G mutation, a shared set of novel mutations (L5F, T95I, D253G, and A701V), and either E484K or S477N, both of which lie within the RBD.
Introduction: Two versions of B.1.526 were identified, both having the D614G and A701V mutations and, in addition, the mutations
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.
Abstract: The most common sets of spike mutations in this lineage (now designated as B.1.526) are L5F, T95I, D253G, E484K or S477N, D614G, and A701V.
Method: Human plasma samples were assayed for neutralization activity against lentiviruses pseudotyped with SARS-CoV-2 spike containing a 21-amino acid cytoplasmic tail deletion and either D614G or mutations corresponding to lineage B.1.526 (L5F, T95I, D253G, E484K, D614G, and A701V).
R
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
PMID: 33907511
2021
International journal of biological sciences
Introduction: The 501Y.V2 variant is characterized by carrying nine mutations in S protein (L18F, D80A, D215G, R246I, Delta242-244, K417N, E484K, N501Y, A701V) (Table 1), three of which (K417N, E484K and N501Y) locate in the RBD of the S protein.
Discussion: shows that an African variant L18F, D80A, D215G, K417N, E484K, N501Y, D614G, A701V propagates much faster than a variant without L18F mutation in the presence of plasma antibodies collected from donors infected in the first wave of epidemic in South Africa (June-August 2020).
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Introduction: To assess the neutralization breadth of RBD-NP-elicited Abs, we evaluated serum neutralizing activity against a panel of pseudotyped viruses comprising wild-type (D614G) SARS-CoV-2 S and nine single-residue SARS-CoV-2 RBD mutants detected in clinical isolates (G446S, Y453F, L455F, T478I, E484A/K, F486L, S494P, and N501Y) as well as the B.1.1.7 (H69-V70 deletion, Y144 deletion, N501Y, A570D, P681H, T716I, PMID: 33735608
2021
Cell
Introduction: Compared against the S protein of the 614G virus shows that 501Y.V2-3's S protein contains 8 mutations: four are located at the NTD (L18F, D80A, D215G, and Del242-244), three are in the viral RBD (K417N, E484K, and N501Y), and one is in the S2 region (A701V).
Introduction: In the early stages of the second wave, 501Y.V2-1 was prevalent; it is identifiable by five amino acid mutations in the S protein (in addition to D614G), including D80A, D215G, E484K,
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Journal of Korean medical science
Browser Board
Co-occurred Entities
Filtrator
ViMRT